PMCF Study on the Safety and Performance of CESPACE 3D
Launched by AESCULAP AG · Jul 17, 2020
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is minimum 18 years old
- • Written informed consent for the documentation of clinical and radiological results
- • Patient's indication according to IFU
- • Patient is not pregnant
- Exclusion Criteria:
- • • Patient is not willing or able to participate at the follow-up examination
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Koblenz, , Germany
Kremmen, , Germany
Patients applied
Trial Officials
Stefan Nikolaus Kroppenstedt, Dr. med.
Principal Investigator
Abteilung für Wirbelsäulenchirurgie Sana Kliniken Sommerfeld
Francis Kilian, Dr. med.
Principal Investigator
Katholisches Klinikum Koblenz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials